Table 2.
Initial findings in patients with pancreas neuroendocrine tumors and at follow-up.
| n (%) | Median (IQR) | |
|---|---|---|
| Patients (n), total | 137 (100%) | |
| G1 | 66 (48.1%)) | |
| G2 | 42 (30.6%) | |
| G2a | 30 (21.8%) | |
| G2b | 12 (8.7%) | |
| Tumor size (cm) | 2 (1.3-5) | |
| G1 | 2.3 (1.5 - 5) | |
| G2 | 4.3 (1.7-6) | |
| G2a | 4 (1.6-6) | |
| G2b | 5.5 (3.9-7.3) | |
| Age (years) | 61 (50-71) | |
| G1 | 62 (54-72) | |
| G2 | 67 (47-69) | |
| G2a | 56.5 (48-65) | |
| G2b | 61 (46-66) | |
| Ki-67 index at first diagnosis | 108 (78.8%) | 2 (1-5) |
| G1 | 1 (1.1.9) | |
| G2 | 5.1 (3.5-9.9) | |
| G2a | 5 (3.3-6.3) | |
| G2b | 11.3 (10-13.5) | |
| Ki-67 index at re-evaluation | 26 (18.9%) | 9.4 (4-13.8) |
| G1 | 4 (3-5.5) | |
| G2 | 12.5 (9-15.5) | |
| G2a | 11.4 (7.8-21.8) | |
| G2b | 13 (12.8-14) | |
| Follow-up (months) | 74 (41-110) | |
| G1 | 65 (41-120) | |
| G2 | 69 (50-92) | |
| G2a | 50 (46-96) | |
| G2b | 62 (48-83) | |
| Functional tumors (n) | 30 (21.8%) | |
| G1 | 15 (10.9%) | |
| G2 | 10 (7.3%) | |
| G2a | 7 (5%) | |
| G2b | 3 (2.2%) | |
| Metastasis at diagnosis, total | 32 (23.3%) | |
| G1 | 9 (6.6%) | |
| G2 | 9 (6.6%) | |
| G2a | 6 (4.4%) | |
| G2b | 4 (2.9%) | |
| Progressive, total* | 42 (30.6%) | |
| G1 | 19 (13.8%) | |
| G2 | 23 (16.7%) | |
| G2a | 14 (102%) | |
| G2b | 9 (6.5%) |
Ki-67 index was evaluated in 108 patients at diagnosis and in 26 during follow-up. All continuous variables are shown as median and interquartile ranges. G1 had a Ki-67 index of <3%, G2 3-20%, G2a 3-9.9% and G2b 10-19.9%. Initial Ki-67 missing in six patients who progressed and by then this index was 10%, 13% and 25%, respectively in three patients. Ki-67 was missing in 5 patients with a functional tumor. F, females. *Patients without initial metastasis. In these patients metastasis developed in median 42 months after surgery (IQR 36-122 months).